HYSINGLA Drug Patent Profile
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
When do Hysingla patents expire, and what generic alternatives are available?
Hysingla is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty-four patents protecting this drug.
The generic ingredient in HYSINGLA is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hysingla
A generic version of HYSINGLA was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.
Summary for HYSINGLA
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for HYSINGLA|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for HYSINGLA|
|DailyMed Link:||HYSINGLA at DailyMed|